Cel­gene vet Bar­er lines up a $23M start­up round for next-gen I/O tech out of Johns Hop­kins

Af­ter spend­ing the past year in the hot seat as chair­man at a bad­ly dys­func­tion­al Te­va, Cel­gene co-fun­der Sol Bar­er can get back to the busi­ness of ramp­ing up biotech star­tups. This morn­ing we re­ceived word that Bar­er has lined up a $23 mil­lion A round to get I/O fledg­ling Nex­Im­mune in­to the clin­ic.

Bar­er, Joshua Bar­er and for­mer Medtron­ic CEO William Hawkins got to­geth­er ear­ly last year — around the time Te­va be­gan to come apart at the seams — to ac­quire the Johns Hop­kins spin­out, based in Gaithers­burg, MD.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA